In this study, two marker panels of CA19-9 and CA-125 or HE4 and CEA were demonstrated to be clinically useful to separate IPMN from PDAC as well as early stage PDAC or CP. Here, CEACAM5 is linked to pancreatic intraductal papillary-mucinous neoplasm.